These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25511243)

  • 1. Why the United States preterm birth rate is declining.
    Schoen CN; Tabbah S; Iams JD; Caughey AB; Berghella V
    Am J Obstet Gynecol; 2015 Aug; 213(2):175-80. PubMed ID: 25511243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options and recommendations to reduce preterm births in women with short cervix.
    Slager J; Lynne S
    J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
    Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
    Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.
    Haram K; Mortensen JH; Morrison JC
    J Matern Fetal Neonatal Med; 2014 Nov; 27(16):1710-5. PubMed ID: 24678618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginal progesterone, cerclage or cervical pessary for preventing preterm birth in asymptomatic singleton pregnant women with a history of preterm birth and a sonographic short cervix.
    Alfirevic Z; Owen J; Carreras Moratonas E; Sharp AN; Szychowski JM; Goya M
    Ultrasound Obstet Gynecol; 2013 Feb; 41(2):146-51. PubMed ID: 22991337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 17-alpha hydroxyprogesterone caproate for preterm birth prevention: Where have we been, how did we get here, and where are we going?
    Manuck TA
    Semin Perinatol; 2017 Dec; 41(8):461-467. PubMed ID: 28947068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assisted reproductive technology surveillance--United States, 2011.
    Sunderam S; Kissin DM; Crawford SB; Folger SG; Jamieson DJ; Barfield WD;
    MMWR Surveill Summ; 2014 Nov; 63(10):1-28. PubMed ID: 25412164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assisted reproductive technology surveillance--United States, 2009.
    Sunderam S; Kissin DM; Flowers L; Anderson JE; Folger SG; Jamieson DJ; Barfield WD;
    MMWR Surveill Summ; 2012 Nov; 61(7):1-23. PubMed ID: 23114281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assisted reproductive technology surveillance -- United States, 2010.
    Sunderam S; Kissin DM; Crawford S; Anderson JE; Folger SG; Jamieson DJ; Barfield WD;
    MMWR Surveill Summ; 2013 Dec; 62(9):1-24. PubMed ID: 24304902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of different progesterone preparations with preterm birth prevention.
    Krispin E; Hadar E; Chen R; Wiznitzer A; Kaplan B
    J Matern Fetal Neonatal Med; 2019 Oct; 32(20):3452-3457. PubMed ID: 29699436
    [No Abstract]   [Full Text] [Related]  

  • 14. Current Preterm Birth Prevention Strategies.
    Breslin N; Gyamfi-Bannerman C
    Clin Perinatol; 2020 Dec; 47(4):705-717. PubMed ID: 33153656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice.
    Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella
    Am J Obstet Gynecol; 2012 May; 206(5):376-86. PubMed ID: 22542113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spontaneous Preterm Birth in Multiples.
    Biggio JR; Anderson S
    Clin Obstet Gynecol; 2015 Sep; 58(3):654-67. PubMed ID: 26083129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing recurrent preterm births: best evidence for transitioning to predictive and preventative strategies.
    Cypher RL
    J Perinat Neonatal Nurs; 2012; 26(3):220-9. PubMed ID: 22843004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
    Co AL; Walker HC; Hade EM; Iams JD
    Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO; Stamilio DM; Macones GA; Polsky D
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
    Caritis SN; Feghali MN; Grobman WA; Rouse DJ;
    Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.